Navigation Links
Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
Date:8/11/2009

BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended June 30, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. ET on August 19, 2009 to September 2, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 330444.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning August 19, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more info
'/>"/>
SOURCE  Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 

Related biology technology :

1. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
2. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
3. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
4. Sinovac Adjourns 2008 Annual General Meeting
5. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
6. Sinovac Completes Construction of H1N1 Virus Seed Bank
7. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
8. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
9. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
10. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
11. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... World,s Top Gene Synthesis Compa...(IGSC) to Coordinate Best Practices in Risk Reduct...of Worldwide Gene Synthesis Capacity , ... the world’s leading gene synthesis companie... common screening protocol to promote biosecurity ...
(Date:11/19/2009)... , VIENNA, Austria, November 19 /PRNewswir...e program on one product candidate at an unexpecte...ate AD02 is planned to enter into,Phase II clinica...y,immediately follows the completion of two Phase ...mpany based its fast decision on the first interim...
(Date:11/18/2009)...ist at the National Institute of Standards and Tec...e, inexpensive method for detecting and measuring ...oxins, invisible spoilage in food or pesticides di...method is more sensitive than conventional techniq... are polarlike water molecules, having distinct el...
(Date:11/18/2009)...PAIGN, Ill. Imagine a polka-dotted postage stamp ...s simply by changing colors. , As reported in th..., Kenneth Suslick and his team at the University o...he general detection of toxic industrial chemicals...works by visualizing odors. This sensor array cou...
Breaking Biology Technology:World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
...s Will be Reported from Phase 2 Studies Evaluating...ctal Cancer and Gastrointestinal Stromal Tumors (G...als, Inc. (Nasdaq: KERX ) today announced that f...y,s Akt-inhibitor for cancer, were accepted for pr...the 45th Annual Meeting of the American Society of...
...RIS, May 18 The Institut Pasteur and Merieux Alli...m research partnership. , The Institut Pasteur...es:,bioMerieux, Transgene, Shantha Biotechnics, AB... and efforts to fight infectious diseases through ...elds: , , - Clinical diagnostics and theranosti...
...E, May 18 /PRNewswire-FirstCall/ - Oncothyreon Inc...ming presentations at the American Society of Clin... 29-June 2, 2009 in Orlando, Florida. Abstracts re...6 and PX-12 are now available to the public online... , , Abstracts include:, - "Long-term safe...
Other Biology Technology:Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology 2Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology 3Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology 4The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases 2The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases 3Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 3
(Date:11/19/2009)...a naturally occurring brain chemical with an unwie..., it can be abused or used as a date-rape drug. ,...e determined new routes by which 4-HB is metaboliz...tion," said K. Michael Gibson, professor and chair...University and a member of the research team. "It...
(Date:11/19/2009)...ON Leaf-cutter ants, which cultivate fungus for f... new one to add to the list: the ant farmers, like...ng bacteria to make their gardens grow. The findin...ience , documents a previously unknown symbiosis b... how leaf-cutter ants have come to dominate the Am...
(Date:11/19/2009)... is an important crop in many countries of the wor...l feed, and industrial materials. It also is consi...tication, molecular evolution, and genome architec...s special collection used the first description of...triguing questions in genetics and plant biology. ...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Like humans, ants use bacteria to make their gardens grow 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4Study Supports Wider Use of Statins 50510 1Study Supports Wider Use of Statins 50510 2Study Supports Wider Use of Statins 50510 3Morphotek 28R 29 Inc Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and 12866 1Morphotek 28R 29 Inc Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and 12866 2Morphotek 28R 29 Inc Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and 12866 3MDS Inc Completes Divestiture of MDS Pharma Services Phase II IV Operations 50506 1MDS Inc Completes Divestiture of MDS Pharma Services Phase II IV Operations 50506 2
...d,s people are infected with tuberculosis, and som...ly hard to treat, requiring a course of multiple a...n,t complete the full course of treatment, which l...he disease. , More effective treatments could be ...llion grant from the National Institutes of Health...
...niversity Medical Center, Chicago, and Ceregene In... to preserve motor function and stop the anatomic,... with Huntington,s disease (HD). This is the first...thod, symptom onset might be prevented in HD mice ...published in the Proceedings of the National Acade...
...spital for Sick Children (SickKids) and the Univer... from adult skin can create neural cell types that...dels of disease. This research is reported in the .... , SickKids researchers previously discovered wh... (called skin-derived precursors, or SKPs) based o...
Other Biology News:Pitt phage hunter takes on tuberculosis 2Gene therapy injected into the brains' of mice with Huntington's disease 2Gene therapy injected into the brains' of mice with Huntington's disease 3Gene therapy injected into the brains' of mice with Huntington's disease 4Stem cells found in adult skin can be transplanted and function in mouse models of disease 2
... 2 real-time PCR detection system uses a fixed arr...) and two photomultiplier tubes for 2-color detect... is built on an DNA Engine thermal cycler, which i...udes the thermal cycler, 96-well sample block, opt...
...allows detection of SYBR Green I or FAM in the fir...ond channel including TET, HEX, VIC, and TAMRA f... allelic discrimination. DNA Engine thermal cycler...e gradient feature permits simultaneous incubation...
Fingerprinting II Dimensioning Techniques from Bio-Rad
DNA Engine Opticon 2 Continuous Fluorescence Detection System from Bio-Rad
Biology Products: